BB
BB Biotech Portfolio holdings
AUM
$3.98B
This Quarter Return
+10.99%
1 Year Return
+15.06%
3 Year Return
+120.36%
5 Year Return
+263.74%
10 Year Return
–
AUM
$3.61B
AUM Growth
+$3.61B
(+10%)
Cap. Flow
+$56.8M
Cap. Flow
% of AUM
1.57%
Top 10 Holdings %
Top 10 Hldgs %
74.41%
Holding
28
New
–
Increased
15
Reduced
4
Closed
1
Top Buys
| 1 |
Esperion Therapeutics
ESPR
|
$29.3M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$25.7M |
| 3 |
Incyte
INCY
|
$17.9M |
| 4 |
RDUS
Radius Health, Inc.
RDUS
|
$17.7M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$15.3M |
Top Sells
| 1 |
KITE
Kite Pharma, Inc.
KITE
|
$66.3M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$12.9M |
| 3 |
CELG
Celgene Corp
CELG
|
$9.48M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$7.98M |
| 5 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$5.83M |
Sector Composition
| 1 | Healthcare | 91.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $464M | 12.85% | 3,184,298 -65,000 | -2% | -$9.48M |
|
|
2
Incyte
INCY
$16.5B
| $428M | 11.85% | 3,668,322 +153,500 | +4% | +$17.9M |
|
|
3
Ionis Pharmaceuticals
IONS
$6.8B
| $399M | 11.03% | 7,861,934 +507,839 | +7% | +$25.7M |
|
4
Gilead Sciences
GILD
$140B
| $225M | 6.22% | 2,774,596 | – | – |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $224M | 6.21% | 1,475,445 | – | – |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $212M | 5.87% | 3,462,753 +16,201 | +0.5% | +$993K |
|
|
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
| $212M | 5.87% | 5,498,799 +460,000 | +9% | +$17.7M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $190M | 5.26% | 1,354,428 | – | – |
|
|
9
Agios Pharmaceuticals
AGIO
$2.19B
| $184M | 5.08% | 2,749,998 -119,530 | -4% | -$7.98M |
|
10
Halozyme
HALO
$8.56B
| $150M | 4.15% | 8,626,051 +360,747 | +4% | +$6.27M |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $131M | 3.61% | 1,111,338 -110,000 | -9% | -$12.9M |
|
|
TSRO
12
DELISTED
TESARO, Inc.
TSRO
| $129M | 3.56% | 996,193 +118,203 | +13% | +$15.3M |
|
|
13
Esperion Therapeutics
ESPR
$448M
| $105M | 2.91% | 2,097,964 +584,422 | +39% | +$29.3M |
|
|
JUNO
14
DELISTED
Juno Therapeutics, Inc.
JUNO
| $92.2M | 2.55% | 2,055,000 -130,000 | -6% | -$5.83M |
|
15
Regeneron Pharmaceuticals
REGN
$61.5B
| $91.7M | 2.54% | 205,000 +25,000 | +14% | +$11.2M |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $68.1M | 1.88% | 1,092,439 +185,000 | +20% | +$11.5M |
|
|
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
| $53.8M | 1.49% | 3,477,882 +160,711 | +5% | +$2.49M |
|
18
MacroGenics
MGNX
$112M
| $44.4M | 1.23% | 2,400,412 +50,300 | +2% | +$930K |
|
|
AVXS
19
DELISTED
AveXis, Inc. Common Stock
AVXS
| $39M | 1.08% | 402,800 | – | – |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $34.7M | 0.96% | 2,200,000 +50,000 | +2% | +$789K |
|
|
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $31.8M | 0.88% | 777,500 | – | – |
|
|
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $28.2M | 0.78% | 485,719 +230,000 | +90% | +$13.3M |
|
|
ALDR
23
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $27.8M | 0.77% | 2,266,008 +325,000 | +17% | +$3.98M |
|
24
Prothena Corp
PRTA
$441M
| $22.7M | 0.63% | 350,000 | – | – |
|
25
Cidara Therapeutics
CDTX
$1.66B
| $10.8M | 0.3% | 1,335,272 +232,694 | +21% | +$1.88M |
|